FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to bispecific polyvalent binding protein capable of binding PD-1 and LAG-3, as well as to an anti-LAG-3 antibody or its antigen-binding part. A composition containing the above-mentioned protein or antibody, as well as a method for the manufacture of a drug are also disclosed.
EFFECT: invention is effective for the treatment of a disorder, in which activity mediated by PD-1 and/or mediated by LAG-3 is harmful.
31 cl, 13 dwg, 55 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| ANTI-CD39 ANTIBODIES, COMPOSITIONS CONTAINING ANTI-CD39 ANTIBODIES AND METHODS OF APPLICATION OF ANTI-CD39 ANTIBODIES | 2018 |
|
RU2795348C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | 2017 |
|
RU2755503C2 |
| ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2838408C1 |
| ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS FOR USE THEREOF | 2021 |
|
RU2839151C1 |
| ANTI-SIGLEC-9 ANTIBODY MOLECULES | 2020 |
|
RU2833330C1 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
